Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2022 Earnings Conference Call April 3, 2023 8:00 AM ET

Company Participants

Alex Lobo - Stern Investor Relations

Milton Werner - President & Chief Executive Officer

Joe Frattaroli - Chief Financial Officer

Conference Call Participants

Operator

Good morning and welcome to the Inhibikase Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded.

I would now like to turn the conference over to Alex Lobo with Stern IR. Please go ahead.

Alex Lobo

Good morning and welcome to Inhibikase Therapeutics fourth quarter and full year 2022 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer. On Friday, March 31, 2023, Inhibikase issued a press release announcing financial results for the full year ended December 31, 2022. We encourage everyone to read Friday's press release as well as Inhibikase's annual report on Form 10-K which has been filed with the SEC. The company's press release and annual report are also available on Inhibikase's website at inhibicase.com. In addition, this conference call is being webcast through the Investor Relations section of the company's website and will be archived there for future reference.

Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, April 3, 2023. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law.

With that said, I would now like to turn the call over to Dr. Milton Werner. Milton, you may begin.

Milton Werner

Thank you, Alex and thank you all for joining us today to review our full year 2022 financial results and recent clinical and business updates. 2022 was an important year for us as we continue to advance our mission to bring disease-modifying therapeutics to patients living with neurodegenerative diseases and cancer. We were excited to continue to advance our lead asset, IkT-148009, in the clinic as well as further validate the underlying mechanism through presentations at several notable scientific and industry conferences.